OTC Markets OTCPK - Delayed Quote USD

Carl Zeiss Meditec AG (CZMWF)

69.42

0.00

(0.00%)

At close: June 12 at 8:00:00 PM EDT

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation.

CNW Group 9 days ago

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec Second Quarter 2025 Earnings: Beats Expectations

Carl Zeiss Meditec ( ETR:AFX ) Second Quarter 2025 Results Key Financial Results Revenue: €560.0m (up 19% from 2Q...

Simply Wall St. 27 days ago

CZMWF
0.00%

CZMWY
3 European Stocks Estimated To Be 39.7% To 44.8% Below Intrinsic Value

As European markets continue to navigate mixed performances amid hopes for easing trade tensions between China and the U.S., investors are increasingly focused on identifying opportunities within this complex landscape. With the pan-European STOXX Europe 600 Index rising for a fourth consecutive week, attention turns to stocks that may be undervalued, offering potential value in an environment shaped by shifting economic policies and market conditions.

Simply Wall St. 29 days ago

OBSJF

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec AG Just Recorded A 37% EPS Beat: Here's What Analysts Are Forecasting Next

A week ago, Carl Zeiss Meditec AG ( ETR:AFX ) came out with a strong set of interim numbers that could potentially lead...

Simply Wall St. 29 days ago

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...

Despite a significant increase in revenue and strong order entries, Carl Zeiss Meditec AG (CZMWF) faces profitability pressures and macroeconomic uncertainties.

GuruFocus.com last month

CZMWY
ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care

ZEISS demonstrates a new standard for the future of ophthalmic research at the Association for Research in Vision and Ophthalmology (ARVO) conference, from May 4 – 8, including the introduction of the new ZEISS Research Data Platform (ZEISS RDP), and a spotlight on the ongoing research collaboration with Boehringer Ingelheim to accelerate personalized, data-driven treatment approaches in ophthalmology.

PR Newswire last month

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec (ETR:AFX) Could Be Struggling To Allocate Capital

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...

Simply Wall St. last month

CZMWF
0.00%

CZMWY
ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone

ZEISS Medical Technology will celebrate the rapid adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25 – 27 in Los Angeles, CA. ZEISS marks a major milestone in the U.S. with more than 2 million digitally planned cases using the ZEISS VERACITY Surgery Planner,1 one of the leading digital planning solutions for cataract surgery, which serves as a testament to

PR Newswire last month

CZMWF
0.00%

CZMWY
ZEISS receives FDA clearance for INTRABEAM 700

As a leading provider of medical solutions in the field of neurosurgery, ZEISS Medical Technology is also dedicated to shaping modern oncology. The company recently received 510(k) clearance from the US Food and Drug Administration (FDA) for INTRABEAM® 700 – a leading-edge platform that provides robotic-assisted precision to support intraoperative radiation therapy (IORT). With its modern digital-first architecture, ZEISS INTRABEAM 700 creates SMART workflow efficiency and provides seamless conn

PR Newswire 2 months ago

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec AG's (ETR:AFX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Carl Zeiss Meditec (ETR:AFX) has had a rough month with its share price down 17%. However, stock prices are usually...

Simply Wall St. 2 months ago

CZMWF
0.00%

CZMWY
ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach

ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has received National Medical Products Administration (NMPA) approval in China, marking a significant milestone in the product's global journey.

PR Newswire 2 months ago

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec AG (ETR:AFX) Stock Goes Ex-Dividend In Just Three Days

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Simply Wall St. 2 months ago

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec's (ETR:AFX) Dividend Will Be Reduced To €0.60

Carl Zeiss Meditec AG ( ETR:AFX ) has announced that on 31st of March, it will be paying a dividend of€0.60, which a...

Simply Wall St. 2 months ago

CZMWF
0.00%

CZMWY
ZEISS Introduces VISULAS Combi in Canada; a Revolutionary Therapeutic Laser Workstation for Enhanced Eye Care

ZEISS Medical Technology announced today the availability in Canada of the ZEISS VISULAS Combi, an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution. Designed for the treatment of retina, cataract, and glaucoma conditions, the ZEISS VISULAS Combi streamlines workflows with customizable modules, a uniform interface, and space-saving features. It enables seamless eye care without the need for time-consumi

CNW Group 2 months ago

CZMWF
0.00%

CZMWY
European Market's Hidden Gems: ASML Holding And 2 Other Value Stocks

In the midst of economic uncertainties and fluctuating indices, the European market has been navigating challenges such as U.S. trade tariffs and monetary policy shifts, with major stock indexes showing mixed performances. Despite these hurdles, opportunities arise for discerning investors to identify undervalued stocks that may offer potential value in a volatile environment.

Simply Wall St. 2 months ago

ASML

ASMLF

EADSF
When Should You Buy Carl Zeiss Meditec AG (ETR:AFX)?

Carl Zeiss Meditec AG ( ETR:AFX ), is not the largest company out there, but it saw a significant share price rise of...

Simply Wall St. 3 months ago

CZMWF
0.00%

CZMWY
ZEISS VISUMAX 800 with SMILE pro software receives approval in China

ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the China market at a time when more than 10 million eyes have been treated with ZEISS SMILE and SMILE pro worldwide, reflecting the technology's broad global momentum driven by strong adoption i

PR Newswire 3 months ago

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Smaller Dividend Than Last Year

Carl Zeiss Meditec AG's ( ETR:AFX ) dividend is being reduced from last year's payment covering the same period to...

Simply Wall St. 3 months ago

CZMWF
0.00%

CZMWY
Carl Zeiss Meditec AG (CZMWF) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Market ...

Despite revenue growth and strategic advancements, Carl Zeiss Meditec AG (CZMWF) faces margin pressures and market uncertainties, particularly in China.

GuruFocus.com 3 months ago

CZMWY
The past three years for Carl Zeiss Meditec (ETR:AFX) investors has not been profitable

Carl Zeiss Meditec AG ( ETR:AFX ) shareholders should be happy to see the share price up 21% in the last month. But...

Simply Wall St. 4 months ago

CZMWF
0.00%

CZMWY

Performance Overview

Return	CZMWF	DAX P (^GDAXI)
YTD	+44.32%	+18.12%
1-Year	-25.27%	+28.75%
3-Year	-47.74%	+75.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Carl Zeiss Meditec AG (CZMWF)

ZEISS CLARUS 700 Receives NMPA Approval in China

Carl Zeiss Meditec Second Quarter 2025 Earnings: Beats Expectations

3 European Stocks Estimated To Be 39.7% To 44.8% Below Intrinsic Value

Carl Zeiss Meditec AG Just Recorded A 37% EPS Beat: Here's What Analysts Are Forecasting Next

Carl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...

ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care

Carl Zeiss Meditec (ETR:AFX) Could Be Struggling To Allocate Capital

ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone

ZEISS receives FDA clearance for INTRABEAM 700

Carl Zeiss Meditec AG's (ETR:AFX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach

Carl Zeiss Meditec AG (ETR:AFX) Stock Goes Ex-Dividend In Just Three Days

Carl Zeiss Meditec's (ETR:AFX) Dividend Will Be Reduced To €0.60

ZEISS Introduces VISULAS Combi in Canada; a Revolutionary Therapeutic Laser Workstation for Enhanced Eye Care

European Market's Hidden Gems: ASML Holding And 2 Other Value Stocks

When Should You Buy Carl Zeiss Meditec AG (ETR:AFX)?

ZEISS VISUMAX 800 with SMILE pro software receives approval in China

Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Smaller Dividend Than Last Year

Carl Zeiss Meditec AG (CZMWF) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Market ...

The past three years for Carl Zeiss Meditec (ETR:AFX) investors has not been profitable

Performance Overview